Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemia

Thus, hypertriglyceridemia represents a target for further intervention. Clinical trials have shown that high-dose eicosapentaenoic acid (EPA) is effective in reducing the risk of atherosclerotic cardiovascular disease (ASCVD) in patients receiving statins, and it is currently being incorporated into combination lipid-modifying therapy strategies for the aggressive treatment of patients at highest risk. This review summarizes the concepts underlying the use of high-dose EPA alongside intensive LDL-lowering therapy, particularly in the context of post-acute coronary syndrome. A practical implementation algorithm is presented, outlining combination therapy treatment options and the role of high-dose EPA in ASCVD prevention in patients with hypertriglyceridemia.

 

https://heart.bmj.com/content/112/2/86?utm_source=alert&utm_medium=email&utm_campaign=heart&utm_content=toc&utm_term=24122025&nbd_source=adestra&nbd=b20a855e0dc44bf8ba4e7ca2b3f506d73126d45c085843816f52dad735a497e6&uaa_id=b20a855e0dc44bf8ba4e7ca2b3f506d73126d45c085843816f52dad735a497e6&utm_campaign=heartjnl-toc%20%28live%29&utm_medium=email&utm_source=adestra